Our team is working to develop novel antiviral compounds to treat Coronavirus and Influenza Virus infections by leveraging our proprietary drug discovery platform.
We are diligently working to leverage our core competencies and decade of experience in the antiviral therapeutics space to combat the global health crisis of COVID-19. Our COVID-19 program consists of work performed globally by contract research organizations and in our own laboratory. Given the growing global need for a treatment, our focus is to advance this program further into preclinical development as quickly and efficiently as possible. Additionally, we are working to advance preclinical candidates under development for the treatment of influenza infection.
